Indian drugmakers with big US exposure as Trump plans pharmaceutical import tariffs
U.S. President Donald Trump said on Tuesday he intends to impose a "25% or higher" levies on semiconductors and pharmaceutical imports, and raise it substantially over the course of a year, a move likely to hit India's sprawling pharmaceutical industry.
Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...
VS Mani, CFO of Glenmark Pharma, discusses the company's strong performance in FY25 with an average of Rs 1,100 crore per ...
Glenmark Pharmaceuticals and FDC Ltd are withdrawing products in the US due to manufacturing problems, as per USFDA reports.
KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1768 in ...
Glenmark Pharmaceuticals share price gained more than 5% during intraday trades on Monday post Q3 Results that were declared ...
Glenmark Pharmaceutical Ltd.'s shares rose over 5% during trade on Monday, after the management highlighted a 300.2% sales ...
We expect our North America business to gain momentum from FY26 onwards, supported by our growing respiratory and injectable ...
Aditya Birla Fashion & Retail and Dish TV will be among 696 firms to release their reports for the Oct-Dec 2024 quarter ...
Glenmark Pharmaceuticals reports strong revenue growth and expansion plans for dermatology and respiratory portfolios in ...
Pharma stocks experienced significant declines due to concerns over new tariffs. Notably, Dr Reddy's, Zydus Lifesciences, and Aurobindo Pharma saw the largest drops. US President Donald Trump's ...
Glenmark Pharmaceuticals Q3 Results 2025:Glenmark Pharmaceuticals declared their Q3 results on 14 Feb, 2025, revealing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback